The FDA has granted Breakthrough Device designation to Castle Biosciences’ DecisionDx-Melanoma test, a gene expression profile assay designed to improve risk stratification and personalized care in cutaneous melanoma.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
Researchers found that breast-conserving treatment provided long-term survival outcomes comparable to mastectomy in patients with breast cancer and BRCA1 or BRCA2 pathogenic variants.
Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.
Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.